top stories

Genen­tech ex­pands deal with mol­e­c­u­lar glue biotech Ori­o­n­is for $105M up­front

1 hour ago
Deals
R&D

Al­tos Labs buys an­ti-ag­ing start­up Do­ri­an Ther­a­peu­tics

3 hours ago
Startups
Deals

How PureTech’s lung fi­bro­sis drug stacks up against the com­pe­ti­tion

1 hour ago
R&D

Re­pro­duc­tive health biotech Re­proNo­vo clos­es $65M Se­ries A

3 hours ago
Financing
Startups

Latest

Most read

Up­dat­ed: Trump ad­min­is­tra­tion re­veals 'most fa­vored na­tion' drug price coun­try tar­gets

21 hours ago
Pharma
Law

UK biotech Ju­ve­nes­cence tar­gets $150M+ for 'healthy lifes­pan' drug can­di­dates

6 hours ago
Financing
Startups

In his first ma­jor pol­i­cy roll­out, Vinay Prasad looks to chal­lenge ex­ist­ing 'dog­ma' on Covid vac­cines

15 hours ago
R&D
FDA+

Up­dat­ed: FDA ad­comm splits votes on Genen­tech and J&J can­cer drugs

16 hours ago
FDA+

CRISPR Ther­a­peu­tics part­ners with siR­NA com­pa­ny, show­ing that gene edit­ing isn’t the on­ly an­swer

17 hours ago
R&D
Cell/Gene Tx

RFK Jr. spars with sen­a­tors over re­search cuts, HHS bud­get plan

17 hours ago
Pharma
FDA+
see latest stream
People

Ex­clu­sive: Weight loss start­up Cal­i­brate swaps CEOs in lat­est lead­er­ship shake­up

22 hours ago

Prime Med­i­cine side­lines on­ly clin­i­cal pro­gram, re­places CEO and lays off some staff

Yesterday

Up­dat­ed: No­vo Nordisk CEO to step down amid stock de­cline, time­line for suc­ces­sor un­known

5 days ago
Financing

Ex­clu­sive: Op­tura rais­es $6.5M to help eval­u­ate health­care AI pro­grams

23 hours ago

Ex­clu­sive: At-home screen­ing start­up Repe­rio Health rais­es $14M

Yesterday

Ex­clu­sive: Cell­Cen­tric col­lects $120M to treat mul­ti­ple myelo­ma with a cap­sule

2 days ago
Startups

Retro Bio­sciences inks blood dis­or­der deal as Sam Alt­man-backed biotech seeks $1B in funds

Yesterday

Ap­n­imed posts first set of Phase 3 sleep ap­nea re­sults, aims for ap­proval fil­ing in 2026

2 days ago

It's been three months with­out a biotech IPO

5 days ago
Deals

Pfiz­er joins PD-1xVEGF race with $1.25B up­front to Chi­nese biotech 3SBio

Yesterday

Why Re­gen­eron is buy­ing 23andMe

Yesterday

Re­gen­eron plans to buy 23andMe for $256M

2 days ago

In FocusSee all

The in­side sto­ry of the six-month sprint to cre­ate the first cus­tom CRISPR ther­a­py for one in­fant’s rare dis­ease

5 days ago
R&D
Cell/Gene Tx

Ex­clu­sive: Drug com­pounder Em­pow­er was built on risky short­cuts, ex-em­ploy­ees and in­spec­tions al­lege

5 days ago
Pharma
Health Tech

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

Last week
R&D
Cell/Gene Tx

The in­side sto­ry of how Sali­o­Gen, a start­up try­ing to wran­gle ‘jump­ing genes’ to make med­i­cines, fell apart

3 weeks ago
Startups

Endpoints Standouts

Will CRISPR mat­ter?

3 months ago
R&D
Special

Big am­bi­tions at Mer­ck and As­traZeneca — along with a few gi­ant pit­falls — re­shape top ranks of the R&D 15

Last month
Bioregnum
R&D

Il­lu­mi­na was built on DNA. Its fu­ture could be bi­ol­o­gy’s next big wave

2 months ago
In Focus
Diagnostics

Where the mon­ey is: The top 100 ven­ture in­vestors in biotech

2 months ago
Financing
Bioregnum

Peer review See all

May
16

No­vo Nordisk’s glob­al obe­si­ty leader is mov­ing on; Flag­ship biotech gets CEO from Schol­ar Rock

May
9

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

May
2

For­mer Tome CEO joins Flag­ship start­up; NGM Bio chief steps down as re­struc­tur­ing takes ef­fect

Apr
25

Paul Stof­fels on re­tir­ing from Gala­pa­gos; Boehringer In­gel­heim switch­es up lead­er­ship

Apr
17

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

Pharma channel feed

Yesterday

Ste­lara biosim­i­lars look to gain trac­tion, helped by re­cent lessons from Hu­mi­ra

Ab­b­Vie's de­fense of its megablock­buster Hu­mi­ra may go down in the his­to­ry books as the poster child for block­ing biosim­i­lar com­pe­ti­tion, but the launch of six Ste­lara biosim­i­lars this year ...

READ MORE

In­tel­li­a's CRISPR ther­a­py like­ly caus­es 'per­ma­nen­t' gene knock­down in AT­TR amy­loi­do­sis

Yesterday
R&D
Cell/Gene Tx

Up­dat­ed: FDA ap­proves No­vavax's Covid vac­cine af­ter six-week de­lay, but for a small­er pop­u­la­tion

2 days ago
FDA+
latest in Pharma

HHS can re­quire ap­proval for drug­mak­ers to ap­ply 340B re­bate mod­els, court rules

4 days ago
Law

FDA pos­es ef­fi­ca­cy, safe­ty ques­tions over four can­cer drugs ahead of two-day ad­comm

4 days ago
FDA+

Amarin calls Hik­ma's drug la­bel ar­gu­ments 'idio­syn­crat­ic,' urges high court to de­cline case

4 days ago
Law

Mark Cuban com­pounder joins Trump's new man­u­fac­tur­ing ini­tia­tive

4 days ago
Manufacturing

Bio­Marin makes Phase 3 buy, pay­ing $270M for rare dis­ease out­fit In­ozyme

4 days ago
Deals
see latest stories

Marketing channel feed

Last month

HHS says it may re­vis­it an­ti-obe­si­ty drug poli­cies af­ter drop­ping Biden-era pro­pos­al

The gov­ern­ment said it “may con­sid­er fu­ture pol­i­cy op­tions” for an­ti-obe­si­ty med­ica­tions, af­ter de­clin­ing to fi­nal­ize a Biden-era pro­pos­al that would have ex­pand­ed cov­er­age to mil­lions ...

READ MORE

RFK Jr. has long crit­i­cized drug ads. He just slashed the FDA of­fice that reg­u­lates them

Last month
Pharma
FDA+

J&J touts new sur­vival da­ta pit­ting lung can­cer com­bo against As­traZeneca's ri­val

Last month
R&D
Pharma
latest in Marketing

No­vo Nordisk slash­es We­govy price by near­ly two-thirds for cash-pay­ing pa­tients

2 months ago
Pharma

Mis­lead­ing ex­hib­it booth pan­el lands NJ drug­mak­er an un­ti­tled let­ter from FDA

2 months ago
FDA+

Eli Lil­ly ex­pands Zep­bound sin­gle-dose vial op­tions at low­er price

2 months ago
Pharma

J&J's new can­cer com­bo beats As­traZeneca's Tagris­so on sur­vival in lung tri­al

4 months ago
Pharma

Drugs are ap­proved — and made avail­able — faster in US than most of EU, da­ta show

5 months ago
Pharma
FDA+
see latest stories

FDA+ channel feed

21 hours ago

Makary, Prasad spell out FDA ground rules for fu­ture Covid vac­cine ap­provals

FDA chief Mar­ty Makary and new CBER Di­rec­tor Vinay Prasad said that fu­ture Covid-19 vac­cine ap­provals will fo­cus on adults over 65 and high-risk peo­ple 6 months to 64 years old, align­ing US ...

READ MORE

Sarep­ta seeks to ex­pand Duchenne gene ther­a­py Ele­v­idys use to tod­dlers

4 days ago
R&D

Deputy FDA chief mulls shak­ing up PDU­FA reau­tho­riza­tion struc­ture

4 days ago
latest in FDA+

RFK Jr. adopts new chikun­gun­ya vac­cine guid­ance; oth­er rec­om­men­da­tions re­main un­der re­view

5 days ago
R&D
Pharma

New CBER chief Prasad is ready­ing 'mas­sive frame­work' around vac­cines, Makary says

5 days ago
Pharma

FDA warns Mayne Phar­ma over 'mis­lead­ing' pre­sen­ta­tion slides on birth con­trol pill

5 days ago

Bio­haven stock sinks on three-month de­lay for neu­ro drug's FDA ap­proval de­ci­sion

6 days ago
Pharma

RFK Jr. de­fends HHS staff cuts, re­or­ga­ni­za­tion plans in House, Sen­ate hear­ings

6 days ago
Pharma
see latest stories

Manufacturing channel feed

5 days ago

'Go ahead and do it': Top RFK Jr. deputy dares drug­mak­ers that might pull man­u­fac­tur­ing over new price pres­sure

NEW YORK — Cal­ley Means, a spe­cial White House em­ploy­ee and top ad­vi­sor to HHS Sec­re­tary Robert F. Kennedy Jr., ef­fec­tive­ly dared Roche to pull its US in­vest­ment af­ter the com­pa­ny said it ...

READ MORE

AGC Bio se­cures lentivi­ral con­tract; Ther­mo Fish­er to make Cy­bin as­set

5 days ago

Up­dat­ed: Mer­ck KGaA con­tin­ues US tar­iff sur­charge but at a 'de­creased' rate 

6 days ago
China
Pharma
latest in Manufacturing

Sanofi touts $20B in­vest­ment in US over five years

6 days ago
Pharma

Some gener­ics, biosim­i­lar drug­mak­ers say they can with­stand tar­iff im­pact

Last week
Pharma

Roche could re­think $50B US ex­pan­sion plan if new poli­cies 'har­m' op­er­a­tions

Last week
Pharma

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

Last week
Pharma

Lon­za says its US-based sites are in high de­mand as phar­ma tar­iffs near

Last week
Pharma
see latest stories
A service from the Financial Times